Erlotinib for the treatment of relapsed non-small cell lung cancer

Health Technology Assessment

Volumn 13, Issue SUPPL.1, 2009, Pages 41-48

  McLeod, C ^a   Bagust, A ^a   Boland, A ^a   Hockenhull, J ^a   Dundar, Y ^a   Proudlove, C ^a   Davis, H ^a   Green, J ^a   Macbeth, F ^a   Stevenson, J ^a   Walley, T ^a   Dickson, R ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TUMOR RECURRENCE;

CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; HUMANS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PROTEIN KINASE INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 70349235564     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta13suppl1/07     Document Type: Article

References (8)

1. National Institute for Health and Clinical Excellence. Guide to the single technology (STA) process. 19 September 2006. URL: www.nice.org.uk/page.aspx?o=STAprocessguide. Cited June 2007.
2. McLeod C, Bagust A, Boland A, Hockenhull J, Dundar Y, Proudlove C, et al. Erlotinib for the treatment of relapsed non-small cell lung cancer. Evidence review group single technology appraisal for NICE. September 2006.
3. National Collaborating Centre for Acute Care. The diagnosis and treatment of lung cancer. Methods, evidence and guidance. 2005. URL: www.rcseng.ac.uk. Cited February 2005.
4. Cancer Research UK. Cancer facts and figures. 2006. URL: www.cancerresearchuk.org/.
5. Hanna N, Shepherd FA, Fossella FV, Pereira JR, Demarinis F, Von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
6. Shepherd FA, Pereira JR, Ciuleanu T, Eng HT, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
7. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy [see comment]. J Clin Oncol 2000;18:2095-103.
8. Australian Department of Health. Public summary document for erlotinib. 2006. URL: www.health.gov.au/internet/wcms/publishing.nsf/Content/pbac-psderlotinibmar06. Cited 2006.